Table 3 Grade 2 or higher late adverse events
No | Age | Sex | Location | T-stage | Group | Dose (Gy, RBE) | Status | Survival (years) | Late adverse event | Grade | Onset from PBT (years) |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 68 | M | Maxillary | 3 | B | 70 | Alive | 4.8 | Vision decreased (IpL) | 3 | 2.2 |
2 | 67 | M | Maxillary | 4a | B | 78 | Alive | 12.3 | Vision decreased (IpL) | 4 | 0.9 |
3 | 61 | M | Ethmoid | 4b | B | 74 | Alive | 8.3 | Retinopathy (IpL) | 3 | 3.3 |
4 | 73 | F | Maxillary | 3 | B | 70 | Alive | 3.8 | Retinopathy (IpL) | 3 | 3.3 |
5 | 47 | M | Nasal | 4b | C | 70 | Alive | 10.1 | Retinopathy (IpL) | 3 | 5.2 |
6 | 66 | F | Maxillary | 4a | C | 74 | Alive | 7 | Retinal vascular disorder (IpL) | 3 | 4.2 |
7 | 64 | F | Ethmoid | 4b | C | 76 | Dead | 1.7 | Central nervous system necrosis | 2 | 0.5 |
8 | 46 | M | Ethmoid | 4b | C | 79.2 | Dead | 4.4 | Central nervous system necrosis | 3 | 1.5 |
9 | 53 | F | Ethmoid | 4b | C | 79.2 | Dead | 3.6 | Fracture | 2 | unknown |